Plain language summaries of study results
Plain language summaries of clinical study results are intended to share the findings of clinical research with study participants, patients and the public in easy-to-understand language. UCB currently provides these summaries for:
- Pivotal studies or studies that were key for the approval of medicines
- Pivotal studies for medicines where clinical development has been terminated globally.
- Plans are underway to expand lay summary development to include additional studies and to provide these summaries in additional languages in the future.
Plain language summaries are also included with other study information via the Compounds drop-down menu on the Clinical Studies Index page.
Bimekizumab
- AS0010 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis
- AS0011 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis
- HS0003 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
- HS0004 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
- PA0010 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active Reference (Adalimumab) Study Evaluating the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
- PA0011 - A Multicenter, Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis.
- PS0008 - Phase 3, Multicenter, Randomized, Double-Blind Study With an Active-Controlled Initial Treatment Period Followed by a Dose-Blind Maintenance Treatment Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
- PS0009 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
- PS0013 - A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study With an Initial Treatment Period Followed by a Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis
- PS0015 - A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
- PS0032 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis
- UP0119 - An Open-Label, Randomized, Parallel-Group, Single-Dose Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants
Brivaracetam
-
N01252 - Brivaracetam for the treatment of partial‑onset seizures (focal seizures) in people from 16 to 70 years old with epilepsy
| pdf file, 279 kb -
N01253 - Brivaracetam for the treatment of partial-onset seizures (focal seizures) in people from 16 to 70 years old with epilepsy
| pdf file, 264 kb -
N01358 - Brivaracetam for the treatment of partial-onset seizures (focal seizures) in people from 16 to 80 years old with epilepsy
| pdf file, 298 kb
Cimzia® (certolizumab pegol)
-
AKS001 - Certolizumab Pegol for the Treatment of Axial Spondyloarthritis in Adults
| pdf file, 33 kb -
C87014 - Certolizumab Pegol for the Treatment of Rheumatoid Arthritis in Adults
| pdf file, 32 kb -
C87027 - Certolizumab Pegol for the Treatment of Rheumatoid Arthritis in Adults
| pdf file, 33 kb -
C87031 - Certolizumab Pegol for the Treatment of Crohn’s Disease in Adults
| pdf file, 33 kb -
C87032 - Certolizumab Pegol for the Treatment of Crohn’s Disease in Adults
| pdf file, 34 kb -
C87050 - Certolizumab Pegol for the Treatment of Rheumatoid Arthritis in Adults
| pdf file, 32 kb -
C87077 - A study to learn if certolizumab pegol plus methotrexate works in participants who are already taking methotrexate
| pdf file, 330 kb -
PS0002 - A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Study Followed by a Dose-Blind Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis
| pdf file, 952 kb -
PS0003 - A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled Study Followed by a Placebo-Controlled Maintenance Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis
| pdf file, 862 kb -
PS0005 - A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Study Followed by a Dose-Blind Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis
| pdf file, 951 kb -
PSA001 - Certolizumab Pegol for the Treatment of Psoriatic Arthritis in Adults
| pdf file, 60 kb -
RA0044 - A study to learn if certolizumab pegol works in Chinese participants with active rheumatoid arthritis
| pdf file, 383 kb -
RA0055 - A multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of certolizumab pegol in combination with methotrexate for inducing and sustaining clinical response in the treatment of DMARD-naïve adults with early active rheumatoid arthritis
| pdf file, 420 kb -
RA0077 - Direct Comparison of Certolizumab Pegol versus Adalimumab in Rheumatoid Arthritis: 2-Year Efficacy and Safety Results from the Randomized EXXELERATE Study
| pdf file, 61 kb -
up0016 - To look at the amount of certolizumab pegol in breast milk (CRADLE)
| pdf file, 237 kb -
up0017 - To look at the transfer of certolizumab pegol across the placenta (CRIB)
| pdf file, 143 kb -
UP0085 - A Postmarketing, Multicenter, Longitudinal, Prospective, Pharmacokinetic, Phase 1b Study In Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia® (Certolizumab Pegol)
| pdf file, 701 kb
Evenity® (romosozumab)
-
20070337 - A Multicenter, International, Randomized, Double-blind, Placebocontrolled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
| pdf file, 621 kb -
20110142 - A Multicenter, International, Randomized, Double-blind, Alendronatecontrolled Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis
| pdf file, 582 kb -
20110174 - A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Compare the Efficacy and Safety of Romosozumab With Placebo in Men With Osteoporosis
| pdf file, 631 kb
Keppra® (levetiracetam)
-
N051 - Evaluation of the efficacy and tolerability of UCB L059 (500 and 1000 mg b.i.d., tablets) add-on treatment in refractory epileptic patients with partial onset seizures: a 32-week double-blind placebo-controlled crossover multicenter trial
| pdf file, 661 kb -
N132 - A study to learn if levetiracetam works in participants with epilepsy who are taking their usual anti-seizure medicines
| pdf file, 426 kb -
N138 - Evaluation of the efficacy and tolerability of ucb L059 (1500 mg b.i.d., 500 mg tablets) monotherapy in epileptic patients with complex partial onset seizures, having experienced improved seizure control under add-on treatment
| pdf file, 686 kb -
N159 - Evaluation of The Efficacy and Tolerability of Levetiracetam Add-On Treatment in Refractory Pediatric Patients With Partial Onset Seizures: A 28-Week Double-Blind, Placebo-Controlled Multi-center Trial
| pdf file, 737 kb -
N01009 - A Double-Blind, Randomized, Multicenter, Placebo-Controlled, In-Patient, Maximum 34 Day Study of Levetiracetam Oral Solution (20-50 mg/kg/day) as Adjunctive Treatment of Refractory Partial Onset Seizures in Pediatric Epileptic Subjects Ranging in Age from 1 Month to Less Than 4 Years of Age
| pdf file, 422 kb -
N01057 - Levetiracetam for the Treatment of Generalised Epilepsy in Children and Adults
| pdf file, 35 kb -
N01061 - A study to learn if levetiracetam works when taken by itself in people with newly diagnosed epilepsy who have focal seizures or grand mal seizures
| pdf file, 563 kb -
N01102 - A Double-blind, Placebo-controlled, Randomized Study: 16-week Evaluation of the Efficacy and Safety of Levetiracetam (LEV) as Add-on Therapy in Adults and Adolescents Older than 16 Years Suffering from Partial Seizures
| pdf file, 358 kb -
N01148 - A study to see if levetiracetam worked and to learn about its safety in children and teenagers 1 month and older with epilepsy
| pdf file, 661 kb -
N01159 - A double-blind, multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of adjunctive treatment with oral levetiracetam (L059) in epilepsy patients aged ≥16 with generalized tonic-clonic (GTC) seizures
| pdf file, 345 kb -
N01221 - A study to learn if levetiracetam works in Japanese participants with epilepsy who are taking their usual anti-seizure medicines
| pdf file, 621 kb -
N01274 - Levetiracetam for the Treatment of Epilepsy in Children (4 - 16 Years Old)
| pdf file, 32 kb -
N01275 - Levetiracetam for Treatment of Epilepsy in Children (1 Month Old to 4 Years Old)
| pdf file, 33 kb -
N01364 - A study to learn if levetiracetam works when taken by itself in Chinese participants with newly diagnosed epilepsy who have focal seizures
| pdf file, 480 kb -
N01375 - A study to learn how levetiracetam worked when taken by itself in Japanese participants with newly diagnosed epilepsy
| pdf file, 595 kb -
N01378 - An open-label, multicenter study to evaluate the safety of adjunctive treatment with intravenous levetiracetam (L059IV) in epilepsy patients aged ≥16 years with partial onset seizures
| pdf file, 541 kb
Neupro® (rotigotine)
-
SP506 - Rotigotine in Adults for the Treatment of Early Parkinson’s Disease
| pdf file, 217 kb -
SP512 - Rotigotine in Adults for the Treatment of Early Parkinson’s Disease
| pdf file, 231 kb -
SP513 - Rotigotine in Adults for the Treatment of Early Parkinson’s Disease
| pdf file, 233 kb -
SP515 - Rotigotine for the Treatment of Advanced Parkinson’s Disease in Adults
| pdf file, 52 kb -
SP650 - Rotigotine in Adults for the Treatment of Advanced Parkinson’s Disease
| pdf file, 245 kb -
SP790 - Rotigotine for the Treatment of Restless Legs Syndrome in Adults
| pdf file, 33 kb -
SP792 - Rotigotine for the Treatment of Restless Legs Syndrome in Adults
| pdf file, 32 kb -
SP0914 - A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of the Efficacy and Safety of the Rotigotine Transdermal Patch in Chinese Subjects with Early-Stage Idiopathic Parkinson’s Disease
| pdf file, 310 kb -
SP1037 - A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Rotigotine Transdermal Patch in Chinese Subjects with Advanced-stage, Idiopathic Parkinson’s Disease Who Are Not Well Controlled on Levodopa
| pdf file, 310 kb
Rozanolixizumab
- TP0003 - Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
- TP0004 - An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia
- UP0106 - A Randomized, Participant-Blind, Investigator-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Rozanolixizumab Administered Subcutaneously Via Manual Push Versus Syringe Driver to Healthy Participants
- MG0003 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
Vimpat® (lacosamide)
-
EP0008 - A study to learn if lacosamide helps control seizures in Chinese and Japanese participants with epilepsy who are taking their usual anti-seizure medicines
| pdf file, 413 kb -
EP0024 - A Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Intravenous Lacosamide as Replacement for Oral Lacosamide in Japanese Adults With Partial-onset Seizures With or Without Secondary Generalization
| pdf file, 286 kb -
SP667 - Lacosamide in Adults for the Treatment of Epileptic Partial Seizures
| pdf file, 139 kb -
SP754 - Lacosamide for the Treatment of Epileptic Partial Seizures in Adolescents (16 years and older) and Adults
| pdf file, 35 kb -
SP755 - Lacosamide for the Treatment of Epileptic Partial Seizures in Adolescents (16 years and older) and Adults
| pdf file, 34 kb -
SP902 - A historical-controlled, multicentre, double blind, randomized trial to assess the efficacy and safety of conversion to lacosamide 400mg/day monotherapy in subjects with partial onset seizures
| pdf file, 388 kb -
SP0969 - A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of lacosamide as adjunctive therapy in subjects with epilepsy ≥4 years to <17 years of age with partial-onset seizures
| pdf file, 284 kb -
SP0982 - A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of lacosamide as adjunctive therapy for uncontrolled primary generalized tonic-clonic seizures in subjects with idiopathic generalized epilepsy
| pdf file, 398 kb -
SP0993 - A multicenter, double-blind, double-dummy, randomized, positive controlled study comparing the efficacy and safety of lacosamide (200 to 600mg/day) to controlled release carbamazepine (400 to 1200mg/day), used as monotherapy in subjects (≥16 years) newly or recently diagnosed with epilepsy and experiencing partial onset or generalized tonic clonic seizures
| pdf file, 444 kb
